undamentalytics Newsletter

Perceptive Advisors LLC: insider trades

Director, 10% owner at 9 companies we cover. 15 open-market purchases and 6 sales not made under a pre-set plan, reported from September 11, 2015 to May 1, 2025.

Would copying Perceptive Advisors LLC’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 13 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on October 23, 2015 into $446 by November 2, 2026, −24.6% a year. The copy held shares only 59% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $27,882, +9.8% a year (the S&P 500 held throughout made $43,607, +14.3% a year). Beta against the index was 0.67. Twelve months after each report, the average purchase was −33.4% against the S&P 500 (median −24.1%), and 39% beat it. Measured from the trade date, the insider’s own timing, the average was −22.2%.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 201520172019202120232025 $43.6k$27.9k$446
Copying Perceptive Advisors LLCS&P 500, same days investedS&P 500, held throughout $10,000 copying Perceptive Advisors LLC’s open-market purchases from October 23, 2015, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−24.6%
S&P 500, same days invested
+9.8% (held throughout +14.3%)
Time in shares
59%
Sharpe ratio (S&P 500)
−0.09 (0.72)
Biggest drop (S&P 500)
−98% (−34%)
Market sensitivity (beta)
0.67
Purchases copied
13

Trade by trade

Perceptive Advisors LLC: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 13 −4.4% −10.9% 31% 7 0.12 0.91 No reliable evidence
Purchases, 6 months after the report 13 −10.1% −13.0% 23% 7 −1.36 0.22 No reliable evidence
Purchases, 12 months after the report 13 −33.4% −24.1% 39% 7 −2.09 0.082 No reliable evidence
Purchases, 12 months after the trade 12 −22.2% −15.3% 42% 6 −1.11 0.32 No reliable evidence
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Aldeyra Therapeutics, Inc. ALDX —80October 22, 2015August 11, 2022
Adma Biologics, Inc. ADMA —21February 11, 2020September 29, 2021
Talphera, Inc. TLPH —02September 11, 2015November 9, 2015
Verrica Pharmaceuticals Inc. VRCA —20December 19, 2023December 26, 2023
Acrivon Therapeutics, Inc. ACRV —02April 29, 2025May 1, 2025
Solid Biosciences Inc. SLDB —10July 29, 2019July 29, 2019
Meiragtx Holdings plc MGTX —10November 24, 2020November 24, 2020
Nautilus Biotechnology, Inc. NAUT —10June 3, 2021June 3, 2021
Yarrow Bioscience, Inc. YARW —01August 17, 2021August 17, 2021

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 1, 2025April 30, 2025 ACRV Sale $1,017,919 not yetnot yetnot yet
April 29, 2025April 25, 2025 ACRV Sale $2,744,946 not yetnot yetnot yet
December 26, 2023December 21, 2023 VRCA Purchase $3,256,191 −27.3%−116.9%−116.4%
December 19, 2023December 15, 2023 VRCA Purchase $6,941,716 −22.7%−115.5%−118.5%
August 11, 2022August 9, 2022 ALDX Purchase $867,750 −19.2%−0.2%−7.9%
August 3, 2022August 1, 2022 ALDX Purchase $728,134 −4.2%+10.1%+45.2%
August 2, 2022July 29, 2022 ALDX Purchase $1,117,279 +2.9%+28.9%+46.1%
September 29, 2021September 24, 2021 ADMA Sale $622,500 not yetnot yetnot yet
August 17, 2021August 13, 2021 YARW Sale $460,000 not yetnot yetnot yet
June 3, 2021June 3, 2021 NAUT Purchase $3,317,002 −29.0%−60.8%−63.4%
January 11, 2021January 7, 2021 ALDX Purchase $9,202,668 −0.2%−90.4%−78.6%
November 24, 2020November 23, 2020 MGTX Purchase $6,425,000 +3.6%+2.4%+12.2%
July 13, 2020July 9, 2020 ALDX Purchase $13,600,000 +12.2%+33.5%+66.7%
March 23, 2020March 19, 2020 ADMA Purchase $1,050,000 not yetnot yetnot yet
February 11, 2020February 11, 2020 ADMA Purchase $15,972,950 not yetnot yetnot yet
July 29, 2019July 25, 2019 SLDB Purchase $13,125,002 +90.8%−69.0%not yet
May 26, 2016May 26, 2016 ALDX Purchase $3,500,000 −13.8%−36.0%−30.5%
November 9, 2015November 5, 2015 TLPH Sale $422,937 not yetnot yetnot yet
November 5, 2015October 28, 2015 ALDX Purchase $293,150 −39.3%−24.1%−22.7%
October 22, 2015October 20, 2015 ALDX Purchase $237,205 −10.9%+3.8%+1.7%
September 11, 2015September 9, 2015 TLPH Sale $1,295,800 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Perceptive Advisors LLC traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.